Article Information
History
- May 13, 2017.
Article Versions
- Version 1 (May 11, 2017 - 08:05).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Seth D. Axen1,
- Xi-Ping Huang2,4,
- Elena L. Cáceres1,3,
- Leo Gendelev1,3,
- Bryan L. Roth2,4,5 and
- Michael J. Keiser1,3,*
- 1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 675 Nelson Rising Ln NS 416A, San Francisco, CA 94143
- 2Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599
- 3Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Diseases, and Institute for Computational Health Sciences, University of California, San Francisco, 675 Nelson Rising Ln NS 416A, San Francisco, CA 94143
- 4National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina, Chapel Hill, North Carolina, USA
- 5Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
- ↵*Corresponding Author E-mail: keiser{at}keiserlab.org. Phone: 415-886-7651.